Oral Obesity Pill Phase 2 Results & Cholesterol Guidelines 2026
Structure Therapeutics reports 16% weight loss in Phase 2 oral GLP-1 trial, plus GSK's Arexvy expansion and new cholesterol guideline updates.
GLP-1 receptor agonists
2 articles tagged "GLP-1 receptor agonists"
Wegovy Linked to Higher Ischemic Optic Neuropathy Risk
New FAERS analysis finds Wegovy carries nearly fivefold higher ischemic optic neuropathy risk vs. Ozempic, raising ocular safety concerns for GLP-1 drugs.
By Sarah Tanaka